HC-HA/PTX3 Complex Isolation and Reconstitution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to identify, isolate, and utilize HC-HA/PTX3 complexes from fetal tissues like the amniotic membrane and umbilical cord for therapeutic applications, such as modulating macrophage polarization and reducing inflammatory responses.
Innovation Solution
Methods for isolating native HC-HA/PTX3 complexes from fetal tissues and producing reconstituted HC-HA/PTX3 complexes in vitro by immobilizing high molecular weight hyaluronan with pentraxin 3 and inter-α-inhibitor proteins, including heavy chain 1 and Tumor necrosis factor α-stimulated gene 6, to promote specific biological activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If native HC-HA/PTX3 complexes are isolated from fetal tissues, then therapeutic efficacy is improved, but isolation complexity and scalability worsen
Solution Approach 1:
The patent extracts and isolates native HC-HA/PTX3 complexes from fetal tissues (amniotic membrane, umbilical cord) using specific biochemical protocols involving differential centrifugation, chromatography, and purification steps. This extraction process enables the separation of the target complex from other tissue components, achieving therapeutic efficacy while managing isolation complexity through systematic purification procedures.
Solution Approach 2:
The patent creates reconstituted HC-HA/PTX3 complexes in vitro by combining purified components (hyaluronan, PTX3 protein, inter-α-inhibitor heavy chain 1) under controlled conditions. This copying approach allows production of therapeutically active complexes without relying solely on scarce fetal tissue sources, thereby improving scalability while maintaining therapeutic efficacy through standardized reconstitution protocols.
2Productivity
If reconstituted HC-HA/PTX3 complexes are produced in vitro, then scalability is improved, but production complexity worsens
Solution Approach 1:
The patent divides the reconstitution process into distinct sequential steps: (1) purification of individual components (hyaluronan, PTX3, inter-α-inhibitor heavy chain 1), (2) assembly of complexes under controlled conditions, and (3) validation of complex formation. This segmentation enables each step to be optimized independently, improving scalability while managing production complexity through modular process design.
Solution Approach 2:
The patent optimizes reconstitution conditions by carefully controlling parameters such as temperature, pH, ionic strength, and component concentrations. By adjusting these parameters, the patent achieves efficient complex formation in vitro, enabling scalable production while managing complexity through standardized protocol development and automation opportunities.
3Object-affected harmful factors
If HC-HA/PTX3 complexes are used to modulate macrophage polarization, then anti-inflammatory effect is improved, but mechanism complexity worsens
Solution Approach 1:
The patent identifies and utilizes specific molecular intermediaries within the HC-HA/PTX3 complex that mediate macrophage polarization. The complex acts as an intermediary substance that binds to receptors on macrophages, triggering signaling pathways that promote M2 anti-inflammatory polarization. This intermediary mechanism enables controlled modulation of immune responses while managing complexity through targeted molecular interaction design.
Data Source
AI summary
Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (IαI). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and kits for use in practicing the methods also are provided.